

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CANbridge Pharmaceuticals Inc.**  
**北海康成製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1228)**

**RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

**RESIGNATION OF THE JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

The board (the “**Board**”) of directors (“**Directors**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) hereby announces that Mr. Wai Chiu Wong (“**Mr. Wong**”), one of the joint company secretaries of the Company has tendered his resignation as joint company secretary of the Company (the “**Joint Company Secretary**”). Mr. Wong has also ceased to act as one of the authorised representatives of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the authorised representative for accepting service of process or notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”), in each case, with effect from March 30, 2026.

Mr. Wong has confirmed that he has no disagreement with the Board and there are no other matters in connection with his resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company.

Following Mr. Wong’s resignation, Ms. Qian Ma (“**Ms. Ma**”), another Joint Company Secretary who is qualified to act as the company secretary of the Company under Rules 3.28 and 8.17 of the Listing Rules, will remain in office and continue to serve as a company secretary of the Company.

## APPOINTMENT OF AUTHORISED REPRESENTATIVE AND PROCESS AGENT

The Board further announces that:

- (1) Ms. Ma has also been appointed as one of the Authorised Representative following the resignation of Mr. Wong as his replacement with effect from March 30, 2026; and
- (2) Ms. Lin Sio Ngo (“**Ms. Lin**”) has been appointed as the Process Agent following the resignation of Mr. Wong as his replacement with effect from March 30, 2026.

The Board would like to express its gratitude to Mr. Wong for his invaluable contributions to the Company during his tenure of service and extend its welcome to Ms. Ma and Ms. Lin on their respective new appointments.

By Order of the Board  
**CANbridge Pharmaceuticals Inc.**  
北海康成製藥有限公司  
**Dr. James Qun Xue**  
*Chairman*

Hong Kong, March 30, 2026

*As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director, Ms. Zhao Wei and Mr. Wang Tingwei as non-executive Directors, and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.*